Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

Antimetastatic Properties of Low Molecular Weight Heparin.

TO THE EDITOR: The well-performed and important FRAGMATIC (Dalteparin in Preventing Blood Clots in Patients With Lung Cancer) trial reported by Macbeth et al concluded that the addition of prophylactic doses of the lowmolecular weight heparin (LMWH) dalteparin for 24 weeks to standard of care in patients with lung cancer did not improve overall survival; the rate of venous thromboembolism was s...

Tinzaparin (innohep®), a Low-molecular-weight Heparin, Reduces Complications of Standard Heparin in Hemodialysis Patients

Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan* Division of Nephrology, Chung Shan Medical University Hospital, Taichung, Taiwan** Department of Biotechnology, Hung Kuang University***, Department of Life Science, Tunghai University**** Received: July, 2004 Revised: April, 2005 Accepted: June, 2005 Address reprint requests to Dr. Ku...

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low molecular weight heparin.

Heparin and low-molecular-weight heparin.

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...